Assessment of genetic markers associated with the development of bronchopulmonary dysplasia in premature infants in the structure of a prognostic model of its development

Introduction. Bronchopulmonary dysplasia (BPD) is a complex disease with a significant genetic predisposition. The aim of the study was to determine genetic markers associated with the development of bronchopulmonary dysplasia in premature infants.

Materials and methods. At Stage 1, whole exome sequencing followed by the bioinformatic analysis of one hundred samples was provided to evaluate the genetic variants. Sequencing data were compared with the data of the children without any congenital pulmonary diseases. At Stage 2, the obtained results were validated using real-time PCR. Further the genotyping of the control group (n = 70) was performed. The obtained frequencies of nucleotide variants were compared between the groups, as well as with general population data using the RUSeq database.

Results. The prevalence of genetic variant rs12489516 in gene CPA3 was significantly higher in the control group of premature infants (p = 0.03; OR = 0.2; 95% CI: 0.02–0.94). Its presence in the genotype reduces the likelihood of developing BPD by 4.76 times. Moreover, statistically significant differences were also identified in the prevalence of rs45488997 in gene CCN2 (p = 0.023). This genetic variant was specific only for children with bronchopulmonary dysplasia. It was also identified that the prevalence of the nucleotide variant rs45488997 in the CCN2 gene was statistically more common among patients with bronchopulmonary dysplasia compared with the general population (p = 0.005). In addition, genetic variants rs5744174 in gene TLR5 and rs2476601 in gene PTPN22 were less frequently observed in the investigated group compared to the general population (p = 0.03 and p = 0.003, respectively).

Conclusion. Identification of genetic markers together with clinical and laboratory data will contribute to the development of an effective predictive model for the calculation of the probability of BPD.

Contribution:
Fisenko A.P. — development of research concept and design, text editing;
Basargina M.A. — development of research concept and design;
Sevostyanov K.V. — development of research concept and design, text editing;
Pushkov A.A. — development of research concept and design;
Davydova I.V. — development of research concept and design, text editing;
Basargina M.A. — collection and processing of data, statistical processing of material and writing text;
Bondar V.A. — data collection and processing; statistical processing of material and writing text;
Zhanin I.S. — performing laboratory research, statistical processing of material.
All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.

Acknowledgements. The study had no sponsorship.

Conflict of interest. The authors declare no conflict of interest.

Received: March 1, 20244

Accepted: March 28, 2024

Published: April 27, 2023

1. Ovsyannikov D.Yu., Davydova I.V., Savost’yanov K.V., Pushkov A.A. Bronchopulmonary Dysplasia [Bronkholegochnaya displaziya]. Moscow: RUDN; 2024. (in Russian)

2. Lavoie P.M., Rayment J.H. Genetics of bronchopulmonary dysplasia: An update. Semin. Perinatol. 2023; 47(6): 151811. https://doi.org/10.1016/j.semperi.2023.151811

3. Bhandari V., Gruen J.R., Jang K.L., Göpel W., Hallman M., Lavoie P.M. Genetics of bronchopulmonary dysplasia: When things do not match up, it is only the beginning. J. Pediatr. 2019; 208: 298–9. https://doi.org/10.1016/j.jpeds.2019.01.014

4. Lal C.V., Ambalavanan N. Genetic predisposition to bronchopulmonary dysplasia. Semin. Perinatol. 2015; 39(8): 584–91. https://doi.org/10.1053/j.semperi.2015.09.004

5. Shaw G.M., O’Brodovich H.M. Progress in understanding the genetics of bronchopulmonary dysplasia. Semin. Perinatol. 2013; 37(2): 85–93. https://doi.org/10.1053/j.semperi.2013.01.004

6. Yang I.V., Schwartz D.A. Epigenetic control of gene expression in the lung. Am. J. Respir. Crit. Care Med. 2011; 183(10): 1295–301. https://doi.org/10.1164/rccm.201010-1579PP

7. Bhandari V., Bizzarro M.J., Shetty A., Zhong X., Page G.P., Zhang H., et al. Familial and genetic susceptibility to major neonatal morbidities in preterm twins. Pediatrics. 2006; 117(6): 1901–6. https://doi.org/10.1542/peds.2005-1414

8. Lavoie P.M., Pham C., Jang K.L. Heritability of bronchopulmonary dysplasia, defined according to the consensus statement of the national institutes of health. Pediatrics. 2008; 122(3): 479–85. https://doi.org/10.1542/peds.2007-2313

9. Pal D., Rao M.R.S. Long noncoding RNAs in pluripotency of stem cells and cell fate specification. Adv. Exp. Med. Biol. 2017; 1008: 223–52. https://doi.org/10.1007/978-981-10-5203-3_8

10. Yu K.H., Li J., Snyder M., Shaw G.M., O’Brodovich H.M. The genetic predisposition to bronchopulmonary dysplasia. Curr. Opin. Pediatr. 2016; 28(3): 318–23. https://doi.org/10.1097/MOP.0000000000000344

11. Mahlman M., Karjalainen M.K., Huusko J.M., Andersson S., Kari M.A., Tammela O.K.T., et al. Genome-wide association study of bronchopulmonary dysplasia: a potential role for variants near the CRP gene. Sci. Rep. 2017; 7(1): 9271. https://doi.org/10.1038/s41598-017-08977-w

12. Torgerson D.G., Ballard P.L., Keller R.L., Oh S.S., Huntsman S., Hu D., et al. Ancestry and genetic associations with bronchopulmonary dysplasia in preterm infants. Am. J. Physiol. Lung Cell. Mol. Physiol. 2018; 315(5): L858–69. https://doi.org/10.1152/ajplung.00073.2018

13. Bondar’ V.A., Davydova I.V., Basargina M.A., Fisenko A.P., Pushkov A.A., Zhanin I.S., et al. The role of genetic predictors in preclinical diagnostics of bronchopulmonary dysplasia. Kremlevskaya meditsina. Klinicheskii vestnik. 2022; (1): 5–9. https://doi.org/10.26269/m7zs-qa37 https://elibrary.ru/qsdtsv (in Russian)

14. Barbitoff Y.A., Khmelkova D.N., Pomerantseva E.A., Slepchenkov A.V., Zubashenko N.A., Mironova I.V., et al. Expanding the Russian allele frequency reference via cross-laboratory data integration: insights from 7,452 exome samples. Expanding the Russian allele frequency reference via cross-laboratory data integration. medRxiv. 2022. Preprint. https://doi.org/10.1101/2021.11.02.21265801

15. Atyakshin D.A., Kostin A.A., Trotsenko I.D., Shishkina V.V., Timann M., Bukhvalov I.B., et al. Carboxypeptidase A3 in the structure of the protease phenotype of mast cells: cytophysiological aspects. Endokrinnaya khirurgiya. 2023; 17(4): 23. https://doi.org/10.14341/serg12846 (in Russian)

16. Sánchez-Ovando S., Baines K.J., Barker D., Wark P.A., Simpson J.L. Six gene and TH2 signature expression in endobronchial biopsies of participants with asthma. Immun. Inflamm. Dis. 2020; 8(1): 40–9. https://doi.org/10.1002/iid3.282

17. Yan Z., Liu L., Jiao L., Wen X., Liu J., Wang N. Bioinformatics analysis and identification of underlying biomarkers potentially linking allergic rhinitis and asthma. Med. Sci. Monit. 2020; 26: e924934. https://doi.org/10.12659/MSM.924934

18. Hültner L., Ehrenreich H. Mast cells and endothelin-1: a life-saving biological liaison? Trends Immunol. 2005; 26(5): 235–8. https://doi.org/10.1016/j.it.2005.03.007

19. Maurer M., Wedemeyer J., Metz M., Piliponsky A.M., Weller K., Chatterje D., et al. Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature. 2004; 432(7016): 512–6. https://doi.org/10.1038/nature03085

20. Wang X., Cui H., Wu S. CTGF: A potential therapeutic target for bronchopulmonary dysplasia. Eur. J. Pharmacol. 2019; 860: 172588. https://doi.org/10.1016/j.ejphar.2019.172588

21. Mathew R. Signaling pathways involved in the development of bronchopulmonary dysplasia and pulmonary hypertension. Children (Basel). 2020; 7(8): 100. https://doi.org/10.3390/children7080100

22. Lim J.S., Jeon E.J., Go H.S., Kim H.J., Kim K.Y., Nguyen T.Q.T., et al. Mucosal TLR5 activation controls healthspan and longevity. Nat. Commun. 2024; 15(1): 46. https://doi.org/10.1038/s41467-023-44263-2

23. Siezen C.L., Bont L., Hodemaekers H.M., Ermers M.J., Doornbos G., Van’t Slot R., et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis in preterm children is associated with airway remodeling genes and innate immune genes. Pediatr. Infect. Dis. J. 2009; 28(4): 333–5. https://doi.org/10.1097/INF.0b013e31818e2aa9

24. Ito R., Barnes E.A., Che X., Alvira C.M., Cornfield D.N. SM22α cell-specific HIF stabilization mitigates hyperoxia-induced neonatal lung injury. Am. J. Physiol. Lung. Cell Mol. Physiol. 2022; 323(2): L129–41. https://doi.org/10.1152/ajplung.00110.2022

25. Purvis H.A., Clarke F., Montgomery A.B., Colas C., Bibby J.A., Cornish G.H., et al. Phosphatase PTPN22 regulates dendritic cell homeostasis and cDC2 dependent T cell responses. Front. Immunol. 2020; 11: 376. https://doi.org/10.3389/fimmu.2020.00376

26. Clarke F., Jordan C.K., Gutiérrez-Martinez E., Bibby J.A., Sanchez-Blanco C., Cornish G.H., et al. Protein tyrosine phosphatase PTPN22 is dispensable for dendritic cell antigen processing and promotion of T-cell activation by dendritic cells. PLoS One. 2017; 12(10): e0186625. https://doi.org/10.1371/journal.pone.0186625

27. Bondar’ V.A. Clinical and Genetic Features of the Development of a New Form of Bronchopulmonary Dysplasia in Premature Infants [Kliniko-geneticheskie osobennosti razvitiya novoi formy bronkholegochnoi displazii u nedonoshennykh detei]. Moscow; 2022. https://elibrary.ru/rfqofu (in Russian)

28. Budding K., van Setten J., van de Graaf E.A., van Rossum O.A., Kardol-Hoefnagel T., Kwakkel-van Erp J.M., et al. The autoimmune-associated single nucleotide polymorphism within PTPN22 correlates with clinical outcome after lung transplantation. Front. Immunol. 2019; 9: 3105. https://doi.org/10.3389/fimmu.2018.03105